Zobrazeno 1 - 10
of 145
pro vyhledávání: '"Peihua, Luo"'
Publikováno v:
IEEE Access, Vol 12, Pp 55146-55156 (2024)
Knowledge tracing aims to predict students’ future question-answering performance based on their historical question-answering records, but the current mainstream knowledge tracing model ignores the individual differences in different students’ k
Externí odkaz:
https://doaj.org/article/efce3abffa4a42b1b312388395848763
Publikováno v:
Zhongguo quanke yixue, Vol 26, Iss 19, Pp 2385-2394 (2023)
Background In China, schizophrenia patients have a high demand for basic medical care, but irrational healthcare-seeking behaviors among them may cause a waste of health resources. So relevant policies have been promulgated to improve the ensuring of
Externí odkaz:
https://doaj.org/article/744c0df9bb2f4ac08650d322f7a0e6b3
Autor:
Hao Yan, Wentong Wu, Yuhuai Hu, Jinjin Li, Jiangxin Xu, Xueqin Chen, Zhifei Xu, Xiaochun Yang, Bo Yang, Qiaojun He, Peihua Luo
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-20 (2023)
Abstract The hepatotoxicity of regorafenib is one of the most noteworthy concerns for patients, however the mechanism is poorly understood. Hence, there is a lack of effective intervention strategies. Here, by comparing the target with sorafenib, we
Externí odkaz:
https://doaj.org/article/9c865dd403c243cd8eab4ad027981d2c
Autor:
Hao Yan, Xiangliang Huang, Jiangxin Xu, Ying Zhang, Jiajia Chen, Zhifei Xu, Hui Li, Zeng Wang, Xiaochun Yang, Bo Yang, Qiaojun He, Peihua Luo
Publikováno v:
Advanced Science, Vol 10, Iss 26, Pp n/a-n/a (2023)
Abstract Nephrotoxicity has become prominent due to the increase in the clinical use of nilotinib, a second‐generation BCR‐ABL1 inhibitor in the first‐line treatment of Philadelphia chromosome‐positive chronic myeloid leukemia. To date, the m
Externí odkaz:
https://doaj.org/article/cb92c02dd21e4c029adaae1fbc56f04b
Publikováno v:
Leukemia & lymphoma [Leuk Lymphoma] 2016 May; Vol. 57 (5), pp. 1243. Date of Electronic Publication: 2016 Mar 07.
Autor:
Ying Jin, Xueqin Chen, Zizheng Gao, Xiaofei Shen, Huangxi Fu, Zezheng Pan, Hao Yan, Bo Yang, Qiaojun He, Zhifei Xu, Peihua Luo
Publikováno v:
Biomedicine & Pharmacotherapy, Vol 144, Iss , Pp 112297- (2021)
High incidence of cutaneous toxicity ranging from 29.2% to 71.2% has been reported during clinical use of vandetanib, which is a multi-target kinase inhibitor indicated for the treatment of unresectable medullary thyroid carcinoma. The cutaneous toxi
Externí odkaz:
https://doaj.org/article/a7701ad358b54f8f823a938022ffeebe
Publikováno v:
Biomedicine & Pharmacotherapy, Vol 143, Iss , Pp 112115- (2021)
Renal fibrosis is a failed wound-healing process of the kidney tissue after chronic, sustained injury, which is a common pathway and pathological marker of virtually every type of chronic kidney disease (CKD), regardless of cause. However, there is a
Externí odkaz:
https://doaj.org/article/e8c12482408443cfb2693f55beb8bb16
Autor:
Zhifei Xu, Zizheng Gao, Huangxi Fu, Yan Zeng, Ying Jin, Bo Xu, Yuanteng Zhang, Zezheng Pan, Xueqin Chen, Xiaochen Zhang, Xiaohong Wang, Hao Yan, Xiaochun Yang, Bo Yang, Qiaojun He, Peihua Luo
Publikováno v:
Cardiovascular Research. 119:1250-1264
Aims Trastuzumab, the first humanized monoclonal antibody that targets human epidermal growth factor receptor 2 (ERBB2/HER2), is currently used as a first-line treatment for HER2 (+) tumours. However, trastuzumab increases the risk of cardiac complic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::aa8eb93852372879755db2ad8e8d4d94
https://doi.org/10.1093/cvr/cvad012
https://doi.org/10.1093/cvr/cvad012
Publikováno v:
Expert Opinion on Therapeutic Targets. 27:71-86
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::540f37eb7f91ec606906ae3344f04e4a
https://doi.org/10.1080/14728222.2023.2177151
https://doi.org/10.1080/14728222.2023.2177151
Publikováno v:
Frontiers in Pharmacology, Vol 11 (2020)
Numerous protein kinases encoded in the genome have become attractive targets for the treatment of different types of cancer. As of January 2020, a total of 52 small-molecule kinase inhibitors (SMKIs) have been approved by the FDA. With the numerous
Externí odkaz:
https://doaj.org/article/03e4173a4cd8465c8baf189f39f34ec5